Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Turnaround In Full Flow As New Products Deliver On Promise

Executive Summary

Takeda Pharmaceutical Co. Ltd. has closed out its "turnaround year" on target, meeting guidance for fiscal 2015. The company has been undergoing a reorganization to pull it through intense generic competition and CEO Christophe Weber took the year-end opportunity to outline how the strategy was playing out for Japanese pharma.

You may also be interested in...

Orexigen Insists It Can Grow Contrave After Takeda Exit

AstraZeneca Builds Another Respiratory Extension With Takeda Deal

AstraZeneca is to pay $575m to acquire full rights to Takeda's Daxas (roflumilast), along with other respiratory assets. The move is the latest in a series of bolt-on acquisitions by the UK firm to bulk up its position in respiratory, one of its core therapeutic franchises along with oncology and cardiovascular/metabolic.

Takeda Enters Generics Space With Teva Tie-Up

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Co. Ltd. are to create a joint business venture to boost the supply of generics to the Japanese market. The new business will be 51% owned by Teva and 49% by Takeda.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts